Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 8/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976064 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4975031 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4976031 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3973513 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL29462307 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3972448 | 0.96 | SLC6A2 (0.93) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3975687 | 0.95 | SLC6A2 (0.93) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL13712049 | 0.90 | SLC6A2 (0.82) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL13712077 | 0.90 | SLC6A2 (0.82) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3961036 | 0.89 | SLC6A2 (0.82) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846105-A2 | USE OF ADRENERGIC ALPHA2B ANTAGONISTS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | Wyeth (US) | 2007-10-24 | — | — | EP | claimed |
| EP-1551413-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | Wyeth a Corporation of the State of Delaware (US) | 2005-07-13 | — | — | EP | claimed |
| EP-1551380-A1 | A METHOD OF TREATING VASOMOTOR SYMPTOMS COMPRISING A COMPOUND HAVING NOREPINEPHRINE REUPTAKE INHIBITOR ACTIVITY AND 5-HT2A ANTAGONISTIC ACTIVITY | Wyeth (US) | 2005-07-13 | — | — | EP | claimed |
| US-20050130987-A1 | Methods of treating vasomotor symptoms | WYETH (US) | 2005-06-16 | — | — | US | claimed |
| WO-2005037260-A2 | USE OF ADRENERGIC ALPHAZE ANTAGONISTS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | WYETH (US) | 2005-04-28 | — | — | WO | claimed |
| US-20040152710-A1 | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms | WYETH | 2004-08-05 | — | — | US | claimed |
| WO-2004035036-A1 | A METHOD OF TREATING VASOMOTOR SYMPTOMS COMPRISING A COMPOUND HAVING NOREPINEPHRINE REUPTAKE INHIBITOR ACTIVITY AND 5-HT2A ANTAGONISTIC ACTIVITY | WYETH (US) | 2004-04-29 | — | — | WO | claimed |
| WO-2004035058-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | WYETH (US) | 2004-04-29 | — | — | WO | claimed |
| EP-0310268-B1 | Substituted cycloalkanols | AMERICAN HOME PROD (US) | 1994-02-02 | — | — | EP | claimed |
| US-4826844-A | ANTIDEPRESSANT, ANXIOLYTIC AGENT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-05-02 | — | — | US | claimed |
| EP-0310268-A2 | Substituted cycloalkanols | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-04-05 | — | — | EP | claimed |
| US-11608339-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-3328835-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3500570-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-05 | — | — | EP | disclosed |
| WO-2004035036-A1 | A METHOD OF TREATING VASOMOTOR SYMPTOMS COMPRISING A COMPOUND HAVING NOREPINEPHRINE REUPTAKE INHIBITOR ACTIVITY AND 5-HT2A ANTAGONISTIC ACTIVITY | WYETH (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035035-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | WYETH (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-0310268-B1 | Substituted cycloalkanols | AMERICAN HOME PROD (US) | 1994-02-02 | — | — | EP | disclosed |
| US-4826844-A | ANTIDEPRESSANT, ANXIOLYTIC AGENT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0310268-A2 | Substituted cycloalkanols | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11608339-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, TPH2 | SLC6A2 52/4885SLC6A3 90/4885SLC6A4 79/4885 |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | SLC6A2 106/4885SLC6A3 162/4885SLC6A4 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.